source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-12-07 12:00:00 | null | LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #CLASSACTION--THE LAW OFFICES OF FRANK R. CRUZ IS INVESTIGATING POTENTIAL CLAIMS AGAINST THE BOARD OF DIRECTORS OF ZYNERBA PHARMACEUTICALS (“ZYNERBA” OR THE “COMPANY”) (NASDAQ: ZYNE) CONCERNING WHETHER THE BOARD BREACHED ITS FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU ARE A SHAREHOLDER, CLICK HERE TO PARTICIPATE. ON SEPTEMBER 18, 2019, ZYNERBA ANNOUNCED RESULTS FROM ITS BELIEVE 1 TRIAL EVALUATING TOPICAL GEL ZYGEL IN CHILDREN AND ADOLESCENTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHA | THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES INVESTIGATION OF ZYNERBA PHARMACEUTICALS (ZYNE) ON BEHALF OF INVESTORS | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-12-04 11:30:00 | null | - NEW EFFICACY DATA DESCRIBE STRONG EVIDENCE OF SEIZURE REDUCTION OVER 12 MONTHS OF TREATMENT, INCLUDING A 73% MEDIAN REDUCTION FROM BASELINE IN MONTHLY SEIZURE FREQUENCY AT MONTH 12 - | ZYNERBA PHARMACEUTICALS PRESENTS NEW DATA IN TWO POSTERS AT THE 2020 ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES) | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-11-23 11:45:00 | null | DEVON, PA., NOV. 23, 2020 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY HAS ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF TWO POSTERS AT THE 2020 VIRTUAL ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES). THE AES ANNUAL MEETING IS BEING HELD VIRTUALLY FROM DECEMBER 4TH THROUGH DECEMBER 8TH, 2020. A COPY OF THE POSTERS WILL BE MADE AVAILABLE ON THE ZYNERBA CORPORATE WEBSITE AT THE TIME OF PRESENTATION AT HTTP://ZYNERBA.COM/PUBLICATIONS/. | ZYNERBA PHARMACEUTICALS ANNOUNCES THE ACCEPTANCE OF TWO POSTERS AT THE 2020 VIRTUAL ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES) | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-11-09 06:45:00 | null | DEVON, PA., NOV. 09, 2020 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ:ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2020, AND PROVIDED AN OVERVIEW OF RECENT OPERATIONAL HIGHLIGHTS. | ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-09-14 09:30:00 | null | ZYNERBA PHARMACEUTICALS PROVIDES UPDATE ON RECENT MILESTONES.ZYNERBA PHARMACEUTICALS INC - FDA SUGGESTS PURSUING INDIVIDUAL SYNDROMES IN DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES PROGRAM.ZYNERBA PHARMACEUTICALS INC - MEETING WITH FDA PLANNED FOR 4Q2020 TO DISCUSS REGULATORY PATH FORWARD FOR ZYGEL.ZYNERBA PHARMACEUTICALS INC - COMPANY IS IN PROCESS OF FINALIZING ITS EVALUATION OF WHICH EPILEPTIC SYNDROMES IT MAY PURSUE WITH ZYGEL. | ZYNERBA SAYS MEETING WITH FDA PLANNED FOR Q4 TO DISCUSS REGULATORY PATH FORWARD FOR ZYGEL | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-08-10 09:30:00 | null | ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q2 LOSS PER SHARE $0.78.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ZYNERBA PHARMACEUTICALS - RECRUITMENT INTO PHASE 2 INSPIRE TRIAL OF ZYGEL IN 22Q DELAYED DUE TO COVID-19 IMPACT IN AUSTRALIA.ZYNERBA PHARMACEUTICALS - BELIEVES CURRENT CASH, EQUIVALENTS SUFFICIENT TO FUND OPERATIONS, CAPITAL REQUIREMENTS INTO Q4 OF 2021. | ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-05-26 09:30:00 | null | ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM OPEN LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH FRAGILE X AT 2020 AMERICAN ACADEMY OF NEUROLOGY (AAN) SCIENCE HIGHLIGHTS VIRTUAL SESSION.ZYNERBA PHARMACEUTICALS INC - TOP LINE RESULTS OF PIVOTAL CONNECT-FX TRIAL EXPECTED LATE IN Q2 OF 2020.ZYNERBA PHARMA - ROBUST RESPONSE SUSTAINED THROUGH TWO YEARS OF TREATMENT WITH ZYGEL IN PATIENTS FROM PHASE 2 FAB-C TRIAL.ZYNERBA PHARMA- DATA SHOW STATISTICALLY SIGNIFICANT IMPROVEMENTS FROM BASELINE THAT WERE OBSERVED AT WEEK 12 WERE SUSTAINED. | ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM OPEN LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH FRAGILE X | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-05-11 10:30:00 | null | ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.53.Q1 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.ZYNERBA - BELIEVES CASH RUNWAY SUFFICIENT TO FUND OPERATIONS BEYOND EXPECTED NDA SUBMISSION, POTENTIAL APPROVAL OF ZYGEL IN FXS & INTO H2 2021. | ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 RESULTS | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-02-03 10:30:00 | null | ZYNERBA PHARMACEUTICALS ANNOUNCES ACHIEVEMENT OF PATIENT SCREENING TARGET FOR PIVOTAL TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME.ZYNERBA PHARMACEUTICALS INC - TOPLINE RESULTS FROM PIVOTAL CONNECT-FX STUDY REMAIN ON TRACK FOR Q2 OF 2020.ZYNERBA PHARMACEUTICALS INC - EXPECTS TO MEET OR EXCEED TARGET OF 204 PATIENTS RANDOMIZED FOR PIVOTAL TRIAL OF ZYGEL. | ZYNERBA PHARMACEUTICALS ANNOUNCES ACHIEVEMENT OF PATIENT SCREENING TARGET FOR PIVOTAL TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-11-06 11:30:00 | null | ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q3 LOSS PER SHARE $0.08.Q3 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.PHASE 2 TOPLINE RESULTS IN AUTISM SPECTRUM DISORDER AND 22Q11.2 DELETION SYNDROME ON TRACK FOR 1H2020.TOPLINE RESULTS FROM PIVOTAL TRIAL IN FRAGILE X SYNDROME ON TRACK FOR 1H2020.COMPANY'S CASH AND CASH EQUIVALENT POSITION AS OF SEPTEMBER 30, 2019 WAS $77.5 MILLION.CASH AND CASH EQUIVALENT POSITION AS OF SEPTEMBER 30, 2019 WAS $77.5 MILLION.EXPECT TO ANNOUNCE TOPLINE RESULTS FOR CONNECT-FX TRIAL IN FIRST HALF OF NEXT YEAR.ZYNERBA- CASH & CASH EQUIVALENT SUFFICIENT TO FUND OPERATIONS,CAPITAL REQUIREMENTS BEYOND EXPECTED NDA SUBMISSION, POTENTIAL APPROVAL OF ZYGEL IN FXS.INTENDS TO MEET WITH FDA IN FIRST HALF OF 2020 TO DISCUSS CLINICAL PATH FORWARD IN DEE.ZYNERBA PHARMACEUTICAL - EXPECTS TO SUBMIT ITS NDA FOR ZYGEL IN FXS TO U.S. FDA IN SECOND HALF OF 2020. | ZYNERBA PHARMACEUTICALS Q3 LOSS PER SHARE $0.08 | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-11-05 22:30:00 | null | ZYNERBA PHARMACEUTICALS, INC. ANNOUNCED EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019. FOR THE THIRD QUARTER, THE COMPANY ANNOUNCED OPERATING LOSS WAS USD 1.926 MILLION COMPARED TO USD 7.985 MILLION A YEAR AGO. NET LOSS WAS USD 1.946 MILLION COMPARED TO USD 7.807 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 0.08 COMPARED TO USD 0.47 A YEAR AGO. FOR THE NINE MONTHS, OPERATING LOSS WAS USD 22.903 MILLION COMPARED TO USD 32.351 MILLION A YEAR AGO. NET LOSS WAS USD 22.228 MILLION COMPARED TO USD 32.120 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 1.03 COMPARED TO USD 2.21 A YEAR AGO. | ZYNERBA PHARMACEUTICALS, INC. REPORTS EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019 | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-10-23 22:30:00 | null | BRAGAR EAGEL & SQUIRE, P.C. ANNOUNCED THAT A CLASS ACTION LAWSUIT HAS BEEN FILED IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA ON BEHALF OF INVESTORS THAT PURCHASED ZYNERBA PHARMACEUTICALS, INC. SECURITIES BETWEEN MARCH 11, 2019 AND SEPTEMBER 17, 2019 (THE CLASS PERIOD). INVESTORS HAVE UNTIL DECEMBER 23, 2019 TO APPLY TO THE COURT TO BE APPOINTED AS LEAD PLAINTIFF IN THE LAWSUIT. ZYNERBA IS DEVELOPING ZYGEL (ZYN002), A TRANSDERMAL CBD GEL, WHICH IS PRESENTLY IN CLINICAL TRIAL. IN APRIL 2018, ZYNERBA INITIATED THE PHASE 2 OF BELIEVE 1 (OPEN LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF ZYGEL ADMINISTERED AS A TRANSDERMAL GEL TO CHILDREN AND ADOLESCENTS WITH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (“DDE”)) CLINICAL TRIAL (“BELIEVE 1 TRIAL”), A SIX-MONTH OPEN LABEL MULTI-DOSE CLINICAL TRIAL DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF ZYGEL IN CHILDREN AND ADOLESCENTS (AGES THREE TO SEVENTEEN YEARS) WITH DEE AS CLASSIFIED BY THE INTERNATIONAL LEAGUE AGAINST EPILEPSY (“ILAE”). ON SEPTEMBER 18, 2019, DURING PRE-MARKET HOURS, ZYNERBA ISSUED A PRESS RELEASE ANNOUNCING RESULTS FROM THE BELIEVE 1 TRIAL EVALUATING TOPICAL GEL ZYGEL IN CHILDREN AND ADOLESCENTS WITH DEE (THE “SEPTEMBER 2019 PRESS RELEASE”). WHILE ZYNERBA ASSERTED THAT ZYGEL WAS WELL-TOLERATED IN THE SEPTEMBER 2019 PRESS RELEASE, IT ALSO DISCLOSED THAT, AMONG PATIENTS ENROLLED IN THE BELIEVE 1 TRIAL, THE RATE OF TREATMENT EMERGENT ADVERSE EVENTS (“TEAES”) WAS 96%, THE RATE OF TREATMENT RELATED ADVERSE EVENTS (“TRAES”) WAS 60%, AND THERE WERE TEN PATIENTS WHO REPORTED SERIOUS ADVERSE EVENTS (“SAES”), OF WHICH, “TWO SAES (LOWER RESPIRATORY TRACT INFECTION AND STATUS EPILEPTICUS) WERE DETERMINED TO BE POSSIBLY RELATED TO TREATMENT.” ON THIS NEWS, ZYNERBA’S STOCK PRICE FELL $2.46 PER SHARE, OR 21.77%, TO CLOSE AT $8.84 PER SHARE ON SEPTEMBER 18, 2019. THE COMPLAINT, FILED ON OCTOBER 23, 2019, ALLEGES THAT THROUGHOUT THE CLASS PERIOD, DEFENDANTS MADE MATERIALLY FALSE AND MISLEADING STATEMENTS REGARDING THE COMPANY’S BUSINESS, OPERATIONAL AND COMPLIANCE POLICIES. SPECIFICALLY, DEFENDANTS MADE FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE THAT: (I) ZYGEL WAS PROVING UNSAFE AND NOT WELL-TOLERATED IN THE BELIEVE 1 TRIAL; (II) THE FOREGOING CREATED A FORESEEABLE, HEIGHTENED RISK THAT ZYNERBA WOULD FAIL TO SECURE THE NECESSARY REGULATORY APPROVALS FOR COMMERCIALIZING ZYGEL FOR THE TREATMENT OF DEE IN CHILDREN AND ADOLESCENTS; AND (III) AS A RESULT, THE COMPANY’S PUBLIC STATEMENTS WERE MATERIALLY FALSE AND MISLEADING AT ALL RELEVANT TIMES. | BRAGAR EAGEL & SQUIRE, P.C. ANNOUNCES CLASS ACTION LAWSUIT AGAINST ZYNERBA PHARMACEUTICALS, INC | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-10-02 22:30:00 | null | ZYNERBA PHARMACEUTICALS, INC. PRESENTS AT BENZINGA CANNABIS CAPITAL CONFERENCE, OCT-23-2019 12:00 PM. VENUE: PALMER HOUSE, A HILTON HOTEL, CHICAGO, ILLINOIS, UNITED STATES. SPEAKERS: JAMES E. FICKENSCHER, CFO, VP OF CORPORATE DEVELOPMENT & TREASURER. | ZYNERBA PHARMACEUTICALS, INC. PRESENTS AT BENZINGA CANNABIS CAPITAL CONFERENCE, OCT-23-2019 12:00 PM | ZYNE | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-07-17 09:15:00 | null | ENGLEWOOD, COLO. , JULY 17, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, HAS WON THE TOP WORKPLACE AWARD AMONG MANUFACTURERS, GIVEN BY ENERGAGE, LLC, AN EMPLOYEE ENGAGEMENT TECHNOLOGY PARTNER. | ZYNEX, INC. (NASD: ZYXI) WINS 2023 NATIONAL TOP WORKPLACES AWARD IN THE MANUFACTURING INDUSTRY CATEGORY | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-07-12 09:15:00 | null | ENGLEWOOD, COLO. , JULY 12, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR SECOND QUARTER 2023 AND REITERATED FULL-YEAR GUIDANCE. | ZYNEX REPORTS PRELIMINARY SECOND QUARTER 2023 RESULTS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-07-10 09:15:00 | null | ENGLEWOOD, COLO. , JULY 10, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, HAS ENGAGED INTERNATIONAL INVESTOR RELATIONS SPECIALISTS MZ GROUP ("MZ") TO LEAD THEIR COMPREHENSIVE STRATEGIC INVESTOR RELATIONS AND FINANCIAL COMMUNICATIONS PROGRAM ACROSS ALL KEY MARKETS. | ZYNEX, INC. ENGAGES MZ GROUP TO LEAD STRATEGIC INVESTOR RELATIONS AND SHAREHOLDER COMMUNICATION PROGRAM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-06-20 09:15:00 | null | ENGLEWOOD, COLO. , JUNE 20, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT THE FDA (FOOD AND DRUG ADMINISTRATION) HAS GRANTED 510(K) MARKET CLEARANCE FOR THE COMPANY'S CM-1600 BLOOD AND FLUID VOLUME MONITORING DEVICE. | ZYNEX RECEIVES FDA CLEARANCE OF CM-1600 MONITOR FOR IMPROVED BLOOD AND FLUID MANAGEMENT | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-06-14 09:15:00 | null | ENGLEWOOD, COLO. , JUNE 14, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS APPROVED A PROGRAM TO BUY BACK $10.0 MILLION OF THE COMPANY'S COMMON STOCK. | ZYNEX ANNOUNCES SHARE BUYBACK PROGRAM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-05-04 21:04:00 | null | ENGLEWOOD, COLO. , MAY 4, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. ("ZYNEX") (NASDAQ: ZYXI), ANNOUNCED TODAY THE PRICING OF ITS PREVIOUSLY ANNOUNCED PRIVATE OFFERING OF $52.5 MILLION AGGREGATE PRINCIPAL AMOUNT OF 5.00% CONVERTIBLE SENIOR NOTES DUE 2026 (THE "NOTES") IN A PRIVATE OFFERING (THE "NOTES OFFERING") TO PERSONS REASONABLY BELIEVED TO BE QUALIFIED INSTITUTIONAL BUYERS PURSUANT TO RULE 144A UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). | ZYNEX PRICES UPSIZED $52.5 MILLION CONVERTIBLE SENIOR NOTES OFFERING | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-05-04 07:30:00 | null | ENGLEWOOD, COLO. , MAY 4, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. ("ZYNEX") (NASDAQ: ZYXI), TODAY ANNOUNCED THAT THOMAS SANDGAARD, ITS CHIEF EXECUTIVE OFFICER (THE "SELLING STOCKHOLDER"), HAS DETERMINED NOT TO PURSUE THE PUBLIC OFFERING OF 2,000,000 SHARES OF THE COMPANY'S COMMON STOCK THAT WAS PREVIOUSLY ANNOUNCED ON MAY 3, 2023 (THE "SECONDARY OFFERING"). | ZYNEX ANNOUNCES UPDATE REGARDING PREVIOUSLY ANNOUNCED OFFERINGS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-05-03 09:15:00 | null | ENGLEWOOD, COLO. , MAY 3, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT IT HAS BEEN NAMED BY THE DENVER POST AS A WINNER OF COLORADO'S TOP WORKPLACES 2023 AWARD. | ZYNEX NAMED AS A WINNER OF COLORADO'S TOP WORKPLACES 2023 BY THE DENVER POST | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-04-11 09:15:00 | null | ENGLEWOOD, COLO. , APRIL 11, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR FIRST QUARTER 2023 AND REITERATED FULL YEAR GUIDANCE. | ZYNEX REPORTS PRELIMINARY FIRST QUARTER 2023 RESULTS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-04-06 09:15:00 | null | ENGLEWOOD, COLO. , APRIL 6, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT IT HAS BEEN RANKED 191 OUT OF 500 ON THE FINANCIAL TIMES FOURTH ANNUAL LIST OF THE AMERICAS' FASTEST GROWING COMPANIES 2023. | ZYNEX EARNS SPOT ON FINANCIAL TIMES LIST OF "THE AMERICAS' FASTEST-GROWING COMPANIES 2023" FOR SECOND CONSECUTIVE YEAR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-04-03 10:20:00 | null | NEW YORK , APRIL 3, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZYNEX, INC. ("ZYNEX" OR THE "COMPANY") (NASDAQ: ZYXI). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. | SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZYNEX, INC. - ZYXI | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-30 23:00:00 | null | NEW YORK--(BUSINESS WIRE)-- #A--BRAGAR EAGEL & SQUIRE, P.C., A NATIONALLY RECOGNIZED STOCKHOLDER RIGHTS LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYNEX, INC. (“ZYNEX” OR THE “COMPANY”) (NASDAQ: ZYXI) ON BEHALF OF ZYNEX STOCKHOLDERS. OUR INVESTIGATION CONCERNS WHETHER ZYNEX HAS VIOLATED THE FEDERAL SECURITIES LAWS AND/OR ENGAGED IN OTHER UNLAWFUL BUSINESS PRACTICES. CLICK HERE TO PARTICIPATE IN THE ACTION. | ZYNEX ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING ZYNEX, INC. ON BEHALF OF ZYNEX STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-30 19:06:00 | null | NEW YORK , MARCH 30, 2023 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, CONTINUES TO INVESTIGATE POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZYNEX, INC. (NASDAQ: ZYXI) RESULTING FROM ALLEGATIONS THAT ZYNEX MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZYNEX SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT. | ROSEN, A LEADING NATIONAL FIRM, ENCOURAGES ZYNEX, INC. INVESTORS TO INQUIRE ABOUT CLASS ACTION INVESTIGATION - ZYXI | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-29 12:20:00 | null | NEW YORK--(BUSINESS WIRE)---- $ZYXI #CLASSACTION--THE LAW FIRM OF KIRBY MCINERNEY LLP IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYNEX, INC. (“ZYNEX” OR THE “COMPANY”) (NASDAQ: ZYXI). THE INVESTIGATION CONCERNS WHETHER ZYNEX AND/OR CERTAIN OF ITS OFFICERS HAVE VIOLATED THE FEDERAL SECURITIES LAWS AND/OR ENGAGED IN OTHER UNLAWFUL BUSINESS PRACTICES. ZYNEX, THROUGH ITS SUBSIDIARY, MARKETS ELECTRO THERAPY PRODUCTS, WHICH HELP IMPROVE THE QUALITY OF LIFE OF PATIENTS WHO HAVE FUNCTIONAL DISABILITIES. | KIRBY MCINERNEY LLP CONTINUES INVESTIGATION OF SHAREHOLDER CLAIMS AGAINST ZYNEX, INC. (ZYXI) | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-22 19:10:00 | null | NEW YORK , MARCH 22, 2023 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZYNEX, INC. ("ZYNEX" OR THE "COMPANY") (NASDAQ: ZYXI). SUCH INVESTORS ARE ADVISED TO CONTACT ROBERT S. | SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZYNEX, INC. - ZYXI | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-21 09:15:00 | null | ENGLEWOOD, COLO. , MARCH 21, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THE DENVER BUSINESS JOURNAL HAS RANKED ZYNEX SIXTH IN A LIST OF THE LARGEST DENVER-AREA BIOTECHNOLOGY/BIOSCIENCE COMPANIES, ACCORDING TO THE NUMBER OF FULL-TIME EMPLOYEES (FTES). | ZYNEX INCLUDED IN DENVER-AREA'S TOP 10 BIOTECHNOLOGY/BIOSCIENCE COMPANIES | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-14 20:45:00 | null | NEW YORK , MARCH 14, 2023 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZYNEX, INC. (NASDAQ: ZYXI) RESULTING FROM ALLEGATIONS THAT ZYNEX MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZYNEX SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT. | ROSEN, LEADING INVESTOR COUNSEL, ENCOURAGES ZYNEX, INC. INVESTORS WITH LOSSES TO INQUIRE ABOUT CLASS ACTION INVESTIGATION - ZYXI | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-13 08:00:00 | null | ENGLEWOOD, COLO. , MARCH 13, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2022. | ZYNEX ANNOUNCES 2022 FOURTH QUARTER AND FULL YEAR EARNINGS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-12 20:30:00 | null | LOS ANGELES, CA / ACCESSWIRE / MARCH 12, 2023 / THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THAT IT IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZYNEX, INC. ("ZYNEX" OR "THE COMPANY") (NASDAQ:ZYXI) FOR VIOLATIONS OF THE SECURITIES LAWS. THE INVESTIGATION FOCUSES ON WHETHER THE COMPANY ISSUED FALSE AND/OR MISLEADING STATEMENTS AND/OR FAILED TO DISCLOSE INFORMATION PERTINENT TO INVESTORS. | SHAREHOLDER ACTION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZYNEX, INC. AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-10 17:13:00 | null | ENGLEWOOD, COLO. , MARCH 10, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) , AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS ON MONDAY, MARCH 13, 2023. | ZYNEX, INC. RESCHEDULES RELEASE OF FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-09 12:33:00 | null | NEW YORK--(BUSINESS WIRE)--WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES AN INVESTIGATION OF POTENTIAL SECURITIES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZYNEX, INC. (NASDAQ: ZYXI) RESULTING FROM ALLEGATIONS THAT ZYNEX MAY HAVE ISSUED MATERIALLY MISLEADING BUSINESS INFORMATION TO THE INVESTING PUBLIC. SO WHAT: IF YOU PURCHASED ZYNEX SECURITIES YOU MAY BE ENTITLED TO COMPENSATION WITHOUT PAYMENT OF ANY OUT OF POCKET FEES OR COSTS THROUGH A CONTINGENCY FEE ARRANGEMENT. | ROSEN, A HIGHLY RECOGNIZED LAW FIRM, ENCOURAGES ZYNEX, INC. INVESTORS WITH LOSSES IN EXCESS OF $100K TO INQUIRE ABOUT CLASS ACTION INVESTIGATION – ZYXI | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-09 12:00:00 | null | LOS ANGELES--(BUSINESS WIRE)---- $ZYXI #ZYXI--THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZYNEX, INC. | INVESTIGATION REMINDER: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZYNEX, INC. AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-08 15:39:00 | null | LOS ANGELES--(BUSINESS WIRE)---- $ZYXI #ZYXI--THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZYNEX, INC. | INVESTIGATION ALERT: THE SCHALL LAW FIRM ANNOUNCES IT IS INVESTIGATING CLAIMS AGAINST ZYNEX, INC. AND ENCOURAGES INVESTORS WITH LOSSES TO CONTACT THE FIRM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-08 14:00:00 | null | LOS ANGELES--(BUSINESS WIRE)--GLANCY PRONGAY & MURRAY LLP (“GPM”), A LEADING NATIONAL SHAREHOLDER RIGHTS LAW FIRM, TODAY ANNOUNCED THAT IT HAS COMMENCED AN INVESTIGATION ON BEHALF OF ZYNEX, INC. (“ZYNEX” OR THE “COMPANY”) (NASDAQ: ZYXI) INVESTORS CONCERNING THE COMPANY'S POSSIBLE VIOLATIONS OF THE FEDERAL SECURITIES LAWS. | GLANCY PRONGAY & MURRAY LLP, A LEADING SECURITIES FRAUD LAW FIRM, ANNOUNCES INVESTIGATION OF ZYNEX, INC. (ZYXI) ON BEHALF OF INVESTORS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-08 10:00:00 | null | BENSALEM, PA.--(BUSINESS WIRE)--LAW OFFICES OF HOWARD G. SMITH ANNOUNCES AN INVESTIGATION ON BEHALF OF ZYNEX, INC. (“ZYNEX” OR THE “COMPANY”) (NASDAQ: ZYXI) INVESTORS CONCERNING THE COMPANY'S POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. ON MARCH 6, 2023, ZYNEX ANNOUNCED THAT THE COMPANY WAS POSTPONING RELEASE OF ITS FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INITIALLY SCHEDULED FOR MARCH 6, 2023 TO ALLOW ADDITIONAL TIME TO COMPLETE ITS YEAR-END CLOSING PROCEDURES. | INVESTOR ALERT: LAW OFFICES OF HOWARD G. SMITH ANNOUNCES INVESTIGATION OF ZYNEX, INC. (ZYXI) ON BEHALF OF INVESTORS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-03-07 19:50:00 | null | LOS ANGELES--(BUSINESS WIRE)--THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES AN INVESTIGATION OF ZYNEX, INC. (“ZYNEX” OR THE “COMPANY”) (NASDAQ: ZYXI) ON BEHALF OF INVESTORS CONCERNING THE COMPANY'S POSSIBLE VIOLATIONS OF FEDERAL SECURITIES LAWS. IF YOU ARE A SHAREHOLDER WHO SUFFERED A LOSS, CLICK HERE TO PARTICIPATE. | THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES INVESTIGATION OF ZYNEX, INC. (ZYXI) ON BEHALF OF INVESTORS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-02-21 09:15:00 | null | ENGLEWOOD, COLO. , FEB. 21, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THE LEASE OF A NEW 41,000 SQUARE FOOT FACILITY TO ACCOMMODATE ZYNEX MONITORING SOLUTION'S (ZMS) CURRENT AND EXPECTED FUTURE GROWTH. | ZYNEX LEASES NEW FACILITY TO ACCOMMODATE GROWTH | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-02-17 09:28:00 | null | ENGLEWOOD, COLO. , FEB. 17, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT IT IS SET TO JOIN THE MSCI USA SMALL CAP INDEX ACCORDING TO THE LIST OF ADDITIONS POSTED BY MSCI ON FEBRUARY 9, 2023. | ZYNEX ANNOUNCES INCLUSION IN MSCI USA SMALL CAP INDEX | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-02-02 14:14:00 | null | DENVER--( BUSINESS WIRE )--INTRINSIC LLC (“INTRINSIC”), A FAST-GROWING VALUATION AND TRANSACTION ADVISORY FIRM WITH EMPLOYEES LOCATED ACROSS A DOZEN U.S. CITIES, ANNOUNCED TODAY THAT ITS TRANSACTION OPINIONS PRACTICE ISSUED TWO FAIRNESS OPINIONS FOR PUBLICLY TRADED CLIENTS IN 2022. GARRETT WILSON, MANAGING DIRECTOR COMMENTED, “WE ARE PROUD AND GRATEFUL THAT OUR PUBLICLY TRADED CLIENTS ARE CLEARLY RECOGNIZING THE BEST-IN-CLASS EXECUTION AND VALUE PROPOSITION THAT HAS BEEN INTRINSIC'S CALLING CARD FOR YEARS IN THE PRIVATE EQUITY, FAMILY OFFICE AND HIGH NET WORTH CLIENTELE COMMUNITIES. EVOLVING DELAWARE COURT OF CHANCERY LEGAL PRECEDENTS AND INCREASING SEC SCRUTINY MAKE INDEPENDENT FAIRNESS OPINIONS A WISE INVESTMENT AS A PART OF BOARDS OF DIRECTORS' FINANCIAL DILIGENCE FOR SIGNIFICANT OR RELATED PARTY M&A. WE LOOK FORWARD TO CONTINUING OUR STRONG MOMENTUM AS A TRUSTED PROVIDER OF FAIRNESS OPINIONS FOR PUBLICLY TRADED COMPANIES.” | INTRINSIC'S GROWING TRANSACTION OPINIONS PRACTICE ISSUED TWO PUBLIC COMPANY FAIRNESS OPINIONS IN 2022 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-02-01 09:15:00 | null | ENGLEWOOD, COLO. , FEB. 1, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION AND PATIENT MONITORING, TODAY REPORTED IT WILL BE HOSTING A BLOOD DONATION DRIVE ON FEBRUARY 1, 2023 AT ITS HEADQUARTERS IN ENGLEWOOD, CO IN PARTNERSHIP WITH VITALANT, THE NATION'S LARGEST INDEPENDENT, NONPROFIT BLOOD SERVICES PROVIDER. | ZYNEX MONITORING ANNOUNCES COMMUNITY BLOOD DRIVE AND RESEARCH COLLABORATION TRIAL FOR ITS FLUID MONITORING SYSTEM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-01-31 09:15:00 | null | ENGLEWOOD, COLO. , JAN. 31, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THE HEALTHCARE TECHNOLOGY REPORT HAS RECOGNIZED ZYNEX IN THE POWER 500 HEALTHCARE TECHNOLOGY COMPANIES. | ZYNEX RECOGNIZED IN THE POWER 500 HEALTHCARE TECHNOLOGY COMPANIES | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2023-01-17 09:15:00 | null | ENGLEWOOD, COLO. , JAN. 17, 2023 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR FOURTH QUARTER 2022 AND REITERATED FULL YEAR GUIDANCE. | ZYNEX REPORTS PRELIMINARY FOURTH QUARTER 2022 RESULTS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-12-22 09:15:00 | null | ENGLEWOOD, COLO. , DEC. 22, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI ), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED IT HAS BEEN RANKED 11TH ON FORBES LIST OF AMERICA'S BEST SMALL COMPANIES FOR 2023. | ZYNEX RANKS 11TH IN FORBES LIST OF "AMERICA'S BEST SMALL COMPANIES 2023" | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-11-21 09:15:00 | null | ENGLEWOOD, COLO. , NOV. 21, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN THE PIPER SANDLER 34TH ANNUAL HEALTHCARE CONFERENCE. | ZYNEX MEDICAL TO PARTICIPATE IN PIPER SANDLER 34TH ANNUAL HEALTHCARE CONFERENCE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-11-17 09:15:00 | null | ENGLEWOOD, COLO. , NOV. 17, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI ), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED IT HAS BEEN RANKED 416TH IN REVENUE GROWTH AMONG ALL COMPANIES IN THE U.S. AND CANADA FOR REVENUE GROWTH BETWEEN 2018 AND 2021 ON DELOITTE'S TECHNOLOGY FAST 500. | ZYNEX NAMED AS A WINNER IN THE DELOITTE 2022 TECHNOLOGY FAST 500TM AWARDS FOR THE 4TH CONSECUTIVE YEAR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-11-01 09:15:00 | null | ENGLEWOOD, COLO. , NOV. 1, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS APPROVED A PROGRAM TO BUY BACK $10.0 MILLION OF THE COMPANY'S COMMON STOCK. | ZYNEX ANNOUNCES ADDITIONAL SHARE BUYBACK PROGRAM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-10-11 09:15:00 | null | ENGLEWOOD, COLO. , OCT. 11, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR THIRD QUARTER 2022 AND REITERATED FULL YEAR GUIDANCE. | ZYNEX REPORTS PRELIMINARY THIRD QUARTER 2022 RESULTS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-09-21 09:15:00 | null | ENGLEWOOD, COLO. , SEPT. 21, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION AND PATIENT MONITORING, TODAY ANNOUNCED IT HAS BEGUN ENROLLMENTS IN A LARGE-SCALE BLOOD LOSS DETECTION CLINICAL TRIAL WITH ITS SECOND-GENERATION MONITORING SYSTEM, THE CM-1600. | ZYNEX MONITORING SOLUTIONS ANNOUNCES FIRST ENROLLMENT IN A BLOOD LOSS DETECTION CLINICAL TRIAL FOR ITS CM-1600 MONITORING SYSTEM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-08-23 09:15:00 | null | ENGLEWOOD, COLO. , AUG. 23, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE VIRTUALLY IN THE GILMARTIN GROUP EMERGING GROWTH COMPANY SHOWCASE ON AUGUST 31 ST, 2022 AT 11:00 AM ET. | ZYNEX MEDICAL TO PARTICIPATE IN INAUGURAL GILMARTIN GROUP EMERGING GROWTH COMPANY SHOWCASE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-08-15 09:15:00 | null | ENGLEWOOD, COLO. , AUG. 15, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED IT HAS STARTED ENROLLMENTS IN AN ONGOING APHERESIS CLINICAL TRIAL WITH ITS SECOND-GENERATION FLUID MONITORING SYSTEM, THE CM-1600. | ZYNEX ANNOUNCES FIRST ENROLLMENTS IN APHERESIS DONATION CLINICAL TRIAL WITH SECOND GENERATION FLUID MONITORING SYSTEM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-08-08 09:00:00 | null | ENGLEWOOD, COLO. , AUG. 8, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THE HEALTHCARE TECHNOLOGY REPORT HAS RECOGNIZED ZYNEX AS 33RD IN THE TOP 100 HEALTHCARE TECHNOLOGY COMPANIES OF 2022. | ZYNEX RECOGNIZED IN TOP 100 HEALTHCARE TECHNOLOGY COMPANIES OF 2022 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-07-11 07:00:00 | null | ENGLEWOOD, COLO. , JULY 11, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR SECOND QUARTER 2022 AND REITERATED FULL YEAR GUIDANCE. | ZYNEX REPORTS PRELIMINARY SECOND QUARTER 2022 RESULTS AND REITERATES FULL YEAR REVENUE AND EBITDA GUIDANCE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-06-13 16:30:00 | null | ENGLEWOOD, COLO. , JUNE 13, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. ("ZYNEX OR THE "COMPANY) (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT IT HAS CHANGED ITS AUDITORS FROM PLANTE & MORAN, PLLC ("PLANTE MORAN") AS THE COMPANY'S INDEPENDENT REGISTERED ACCOUNTING FIRM TO MARCUM LLP EFFECTIVE JUNE 13, 2022. | ZYNEX ANNOUNCES CHANGE OF AUDITOR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-05-03 07:00:00 | null | ENGLEWOOD, COLO. , MAY 3, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, RANKED 250 OUT OF 500 ON THE FINANCIAL TIMES LIST OF AMERICAS' FASTEST GROWING COMPANIES IN 2022. | ZYNEX RANKS 250 IN FINANCIAL TIMES LIST OF "THE AMERICAS' FASTEST GROWING COMPANIES 2022" | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-04-11 09:15:00 | null | ENGLEWOOD, COLO. , APRIL 11, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION AND PATIENT MONITORING, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS APPROVED A PROGRAM TO BUY BACK $10.0 MILLION OF THE COMPANY'S COMMON STOCK. | ZYNEX ANNOUNCES SHARE BUYBACK PROGRAM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-04-08 07:00:00 | null | ENGLEWOOD, COLO. , APRIL 8, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED PRELIMINARY RESULTS FOR FIRST QUARTER 2022, AFFIRMING GUIDANCE FOR REVENUE, EBITDA AND ORDER GROWTH. | ZYNEX REPORTS PRELIMINARY FIRST QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-03-23 07:01:00 | null | ENGLEWOOD, COLO., MARCH 23, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI) AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THE DENVER BUSINESS JOURNAL HAS RECOGNIZED ZYNEX AS THE FOURTH LARGEST BIOTECHNOLOGY/BIOSCIENCE PUBLIC COMPANY IN COLORADO BASED ON NUMBER OF COMPANYWIDE EMPLOYEES AS OF NOVEMBER 1, 2021. | ZYNEX RECOGNIZED AS FOURTH LARGEST BIOTECHNOLOGY/BIOSCIENCE COMPANY IN COLORADO | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-02-18 07:00:00 | null | ENGLEWOOD, COLO., FEB. 18, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY RESPONDED TO A SHORT REPORT RELATED TO UNITED HEALTH CARE'S PRESCRIPTION COVERAGE OF ITS PRODUCTS. | ZYNEX ANTICIPATES NO MATERIAL CHANGE IN REVENUE FROM SWITCH IN UNITED HEALTH CARE PRESCRIPTION COVERAGE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-01-20 07:04:00 | null | ENGLEWOOD, COLO., JAN. 20, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED IT IS ADDING POST-OPERATIVE AND OA (OSTEOARTHRITIS) KNEE BRACES TO ITS LINE OF PAIN AND REHABILITATION PRODUCTS. | ZYNEX ADDS KNEE BRACING TO ITS PAIN MANAGEMENT DIVISION | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2022-01-03 09:00:00 | null | ENGLEWOOD, COLO., JAN. 3, 2022 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED THAT IT HAS SUBMITTED A 510(K) APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION ("FDA") FOR THE CM-1600, ITS NEXT GENERATION FLUID MONITORING SYSTEM. | ZYNEX SUBMITS FDA APPLICATION FOR ITS NEXT GENERATION FLUID AND BLOOD VOLUME MONITOR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-12-23 09:00:00 | null | ENGLEWOOD, COLO., DEC. 23, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NONINVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION, AND PATIENT MONITORING, TODAY ANNOUNCED IT HAS ACQUIRED 100% OF KESTREL LABS, INC., A LASER-BASED, NONINVASIVE PATIENT MONITORING TECHNOLOGY COMPANY. | ZYNEX ANNOUNCES ACQUISITION OF KESTREL LABS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-12-20 09:15:00 | null | ENGLEWOOD, COLO. , DEC. 20, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, REHABILITATION AND PATIENT MONITORING, TODAY REPORTED IT HAS STARTED ENROLLMENTS IN A HEMODIALYSIS CLINICAL TRIAL WITH ITS FLUID MONITORING SYSTEM, CM-1500. | ZYNEX MONITORING ANNOUNCES FIRST ENROLLMENT IN A HEMODIALYSIS CLINICAL TRIAL FOR ITS FLUID MONITORING SYSTEM | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-11-18 09:15:00 | null | ENGLEWOOD, COLO., NOV. 18, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. | ZYNEX RANKED 7TH IN REVENUE GROWTH AMONG MEDICAL DEVICE COMPANIES | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-11-10 09:15:00 | null | ENGLEWOOD, COLO., NOV. 10, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED IT HAS DECLARED A ONE-TIME SPECIAL CASH DIVIDEND OF $0.10 PER SHARE AND A STOCK DIVIDEND OF 10% PER SHARE. | ZYNEX DECLARES SPECIAL CASH DIVIDEND OF $0.10 PER SHARE AND 10% STOCK DIVIDEND | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-11-03 09:15:00 | null | ENGLEWOOD, COLO., NOV. 3, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED ITS 25TH ANNIVERSARY. | ZYNEX CELEBRATES 25TH ANNIVERSARY | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-11-02 16:01:00 | null | ENGLEWOOD, COLO., NOV. 2, 2021 /PRNEWSWIRE/ -- 2021 THIRD QUARTER REVENUE INCREASED 74% YEAR OVER YEAR TO $34.8 MILLION ORDERS INCREASED 70% RECORD NET INCOME OF $6.1 MILLION; DILUTED EPS $0.17 ADJUSTED EBITDA $9.3 MILLION ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY REPORTED FINANCIAL RESULTS FOR ITS THIRD QUARTER ENDED SEPTEMBER 30, 2021. | ZYNEX ANNOUNCES 2021 THIRD QUARTER EARNINGS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-10-25 09:15:00 | null | ENGLEWOOD, COLO., OCT. 25, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, ANNOUNCED TODAY THAT IT WILL HOST THE COMPANY'S 2021 THIRD QUARTER EARNINGS INVESTOR WEBCAST ON TUESDAY, NOVEMBER 2, 2021 AT 2:15 P.M. | ZYNEX SCHEDULES 2021 THIRD QUARTER EARNINGS CALL | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-10-13 09:15:00 | null | ENGLEWOOD, COLO., OCT. 13, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN MANUFACTURING AND SELLING NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED ORDERS AND AN INCREASED ADJUSTED EBITDA ESTIMATE FOR Q3 2021. | ZYNEX ANNOUNCES 70% ORDER GROWTH AND INCREASES Q3 2021 ADJUSTED EBITDA ESTIMATE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-10-08 09:15:00 | null | ENGLEWOOD, COLO., OCT. 8, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED THAT ZYNEX MONITORING SOLUTIONS WILL ATTEND AND DISPLAY THE CM-1500 FLUID MANAGEMENT DEVICE AT THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS ANNUAL CONFERENCE FROM OCTOBER 8 – 12 IN SAN DIEGO. | ZYNEX TO DISPLAY ITS CM-1500 FLUID MONITORING SYSTEM AT THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS ANNUAL CONFERENCE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-07-21 09:15:00 | null | ENGLEWOOD, COLO., JULY 21, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, ANNOUNCED TODAY THAT IT WILL HOST THE COMPANY'S 2021 SECOND QUARTER EARNINGS INVESTOR WEBCAST ON THURSDAY, JULY 29, 2021 AT 2:15 P.M. | ZYNEX SCHEDULES 2021 SECOND QUARTER EARNINGS CALL | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-07-15 09:15:00 | null | ENGLEWOOD, COLO., JULY 15, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN MANUFACTURING AND SELLING NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED ORDERS AND AN INCREASED ADJUSTED EBITDA ESTIMATE FOR Q2 2021. | ZYNEX ANNOUNCES 247% ORDER GROWTH AND INCREASES Q2 ADJUSTED EBITDA ESTIMATE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-07-13 09:15:00 | null | ENGLEWOOD, COLO., JULY 13, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED THAT EFFECTIVE AS OF MARKET OPEN ON JULY 14, 2021, ITS COMMON STOCK HAS BEEN APPROVED FOR UPLISTING TO THE NASDAQ GLOBAL SELECT MARKET® AND WILL CONTINUE TRADING UNDER ITS CURRENT TICKER SYMBOL "ZYXI. | ZYNEX ANNOUNCES UPLISTING TO THE NASDAQ GLOBAL SELECT MARKET® | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-04-20 09:15:00 | null | ENGLEWOOD, COLO., APRIL 20, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS TODAY ANNOUNCED THAT IT HAS HIRED DONALD GREGG AS THE VICE PRESIDENT OF SALES AND OPERATIONS OF ITS MONITORING SOLUTIONS DIVISION. | ZYNEX APPOINTS DONALD GREGG AS VICE PRESIDENT OF SALES AND OPERATIONS OF MONITORING SOLUTIONS DIVISION | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-04-19 09:15:00 | null | ENGLEWOOD, COLO., APRIL 19, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, ANNOUNCED TODAY THAT IT WILL HOST THE COMPANY'S 2021 FIRST QUARTER EARNINGS INVESTOR WEBCAST ON THURSDAY, APRIL 29, 2021 AT 2:15 P.M. | ZYNEX SCHEDULES 2021 FIRST QUARTER EARNINGS CALL | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-04-12 09:15:00 | null | ENGLEWOOD, COLO., APRIL 12, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN MANUFACTURING AND SELLING NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED ORDERS FOR Q1 2021. | ZYNEX ANNOUNCES 140% YEAR OVER YEAR ORDER GROWTH IN Q1-2021 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-04-09 09:15:00 | null | ENGLEWOOD, COLO., APRIL 9, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY ANNOUNCED THAT IT IS MOVING TO A NEW CORPORATE HEADQUARTERS TO ACCOMMODATE ITS' CONTINUED GROWTH. | ZYNEX GROWTH LEADS TO NEW CORPORATE HEADQUARTERS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-03-30 09:15:00 | null | ENGLEWOOD, COLO., MARCH 30, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS TODAY ANNOUNCED THE DENVER BUSINESS JOURNAL HAS RECOGNIZED ZYNEX AS THE SIXTH LARGEST BIOTECHNOLOGY/BIOSCIENCE PUBLIC COMPANY IN COLORADO BASED ON NUMBER OF COMPANYWIDE EMPLOYEES AS OF NOVEMBER 1, 2020. | ZYNEX RECOGNIZED AS THE SIXTH LARGEST BIOTECHNOLOGY/BIOSCIENCE COMPANY IN COLORADO | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-02-18 09:15:00 | null | ENGLEWOOD, COLO., FEB. 18, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS,... | ZYNEX SCHEDULES 2020 FOURTH QUARTER AND FULL-YEAR EARNINGS CALL | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-01-28 16:30:00 | null | ENGLEWOOD, COLO., JAN. 28, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS TODAY... | ZYNEX APPOINTS ANNA LUCSOK AS CHIEF OPERATING OFFICER OF ZYNEX MEDICAL | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-01-14 09:15:00 | null | ENGLEWOOD, COLO., JAN. 14, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY... | ZYNEX ANNOUNCES FILING OF PATENT FOR SEPSIS MONITOR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2021-01-06 09:15:00 | null | ENGLEWOOD, COLO., JAN. 6, 2021 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS, TODAY... | ZYNEX ANNOUNCES A SECOND UTILITY PATENT FOR ITS BLOOD VOLUME MONITOR | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-11-19 09:15:00 | null | ENGLEWOOD, COLO., NOV. 19, 2020 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS TODAY... | ZYNEX RANKED 13TH IN REVENUE GROWTH AMONG MEDICAL DEVICE COMPANIES | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-11-17 09:15:00 | null | ENGLEWOOD, COLO., NOV. 17, 2020 /PRNEWSWIRE/ -- ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE MANUFACTURE AND SALE OF NON-INVASIVE MEDICAL DEVICES FOR PAIN MANAGEMENT, STROKE REHABILITATION, CARDIAC MONITORING AND NEUROLOGICAL DIAGNOSTICS TODAY... | ZYNEX TO PARTICIPATE IN THE PIPER SANDLER 32ND ANNUAL VIRTUAL HEALTHCARE CONFERENCE | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-10-27 16:01:00 | null | ENGLEWOOD, COLO., OCT. 27, 2020 /PRNEWSWIRE/ -- REVENUE INCREASED 69% YEAR OVER YEAR TO $20.0 MILLION ORDERS INCREASED 96% NET INCOME OF $1.3 MILLION; DILUTED EPS $0.04 ADJUSTED EBITDA $2.4 MILLION ZYNEX, INC. (NASDAQ: ZYXI), AN INNOVATIVE MEDICAL TECHNOLOGY COMPANY SPECIALIZING IN THE... | ZYNEX ANNOUNCES THIRD QUARTER 2020 EARNINGS | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-07-28 18:30:00 | null | ZYNEX ANNOUNCES SECOND QUARTER 2020 EARNINGS.Q2 REVENUE $19.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19.1 MILLION.Q2 EARNINGS PER SHARE $0.09.SEES FY 2020 REVENUE UP ABOUT 76 TO 87 PERCENT.SEES Q3 2020 REVENUE UP ABOUT 89 TO 93 PERCENT.Q2 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA.SEES Q3 REVENUE BETWEEN $22.3 MILLION AND $22.8 MILLION.SEES FY REVENUE ESTIMATED BETWEEN $80.0 MILLION AND $85.0 MILLION. | ZYNEX Q2 EARNINGS PER SHARE $0.09 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-07-15 05:30:00 | null | ZYNEX, INC. PRICES PUBLIC OFFERING OF COMMON STOCK.ZYNEX INC - ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF AN AGGREGATE OF 2.5 MILLION SHARES OF ITS COMMON STOCK AT PUBLIC OFFERING PRICE OF $22.00 PER SHARE. | ZYNEX, INC. PRICES PUBLIC OFFERING OF COMMON STOCK | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-07-14 18:30:00 | null | ZYNEX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ZYNEX - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING TO EXPAND SALES FORCE AND MARKETING ACTIVITIES.ZYNEX INC - CO & CERTAIN OF STOCKHOLDERS ARE PROPOSING TO SELL SHARES OF COMMON STOCK IN PROPOSED OFFERING.ZYNEX - INTENDS TO USE NET PROCEEDS FROM PROPOSED OFFERING ALSO TO LAUNCH CO'S BLOOD VOLUME MONITOR. | ZYNEX INC ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-07-09 11:30:00 | null | ZYNEX ANNOUNCES 37% ORDER GROWTH AND INCREASES Q2 AND FULL-YEAR REVENUE ESTIMATES.SEES FY REVENUE UP ABOUT 76 TO 87 PERCENT.SEES FY 2020 REVENUE $80 MILLION TO $85 MILLION. | ZYNEX ANNOUNCES 37% ORDER GROWTH AND INCREASES Q2 AND FULL-YEAR REVENUE ESTIMATES | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-04-28 18:30:00 | null | ZYNEX ANNOUNCES 2020 FIRST QUARTER EARNINGS.Q1 REVENUE $15.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.6 MILLION.Q1 EARNINGS PER SHARE $0.09.SEES Q2 REVENUE $17.5 MILLION TO $18 MILLION.SEES FY 2020 REVENUE UP ABOUT 72 TO 83 PERCENT.SEES Q2 2020 REVENUE UP ABOUT 70 TO 75 PERCENT.Q1 EARNINGS PER SHARE ESTIMATE $0.06 -- REFINITIV IBES DATA.SEES Q2 ADJUSTED EBITDA BETWEEN $3.2 AND $3.7 MILLION.FULL YEAR 2020 ESTIMATES ARE UNCHANGED.. | ZYNEX SEES FY 2020 REVENUE UP ABOUT 72 TO 83 PERCENT | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-02-27 21:30:00 | null | ZYNEX ANNOUNCES 2019 FOURTH QUARTER AND FULL YEAR EARNINGS.ZYNEX INC <<<ZYXI.O>>> Q4 EARNINGS PER SHARE $0.09.ZYNEX INC <<<ZYXI.O>>> Q4 REVENUE $14.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.8 MILLION.ZYNEX INC <<<ZYXI.O>>> SEES FY 2020 REVENUE $75 MILLION TO $80 MILLION.ZYNEX INC <<<ZYXI.O>>> SEES Q1 REVENUE $14 MILLION TO $14.5 MILLION.ZYNEX INC <<<ZYXI.O>>> SEES FY 2020 REVENUE UP ABOUT 65 TO 76 PERCENT.ZYNEX INC <<<ZYXI.O>>> SEES Q1 2020 REVENUE UP ABOUT 52 TO 58 PERCENT.ZYNEX INC <<<ZYXI.O>>> Q4 EARNINGS PER SHARE ESTIMATE $0.08 -- REFINITIV IBES DATA.ZYNEX INC -EXPECT ADDITION OF NEW SALES REPS TO HAVE AN IMPACT ON ORDER AND REVENUE GROWTH THIS YEAR. | ZYNEX Q4 EARNINGS PER SHARE $0.09 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-02-27 19:30:00 | null | ZYNEX ANNOUNCES 2019 FOURTH QUARTER AND FULL YEAR EARNINGS.Q4 REVENUE $14.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.8 MILLION.Q4 EARNINGS PER SHARE $0.28.SEES FY 2020 REVENUE $75 MILLION TO $80 MILLION.SEES Q1 REVENUE $14 MILLION TO $14.5 MILLION.SEES FY 2020 REVENUE UP ABOUT 65 TO 76 PERCENT.SEES Q1 2020 REVENUE UP ABOUT 52 TO 58 PERCENT.Q4 EARNINGS PER SHARE ESTIMATE $0.08 -- REFINITIV IBES DATA.ZYNEX - EXPECT ADDITION OF NEW SALES REPS TO HAVE AN IMPACT ON ORDER AND REVENUE GROWTH THIS YEAR. | ZYNEX ANNOUNCES Q4 EARNINGS PER SHARE $0.28 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-01-09 12:30:00 | null | SEES FY REVENUE $45.3 MILLION TO $45.8 MILLION.SEES Q4 REVENUE $14 MILLION TO $14.5 MILLION.ORDERS IN Q4 WERE 129% ABOVE NUMBER OF ORDERS IN Q4 OF 2018.ZYNEX - Q4 2019 ESTIMATED ADJUSTED EBITDA HAS BEEN UPDATED TO BETWEEN $3.6 AND $4.1 MILLION.Q4 REVENUE VIEW $12.8 MILLION -- REFINITIV IBES DATA. | ZYNEX SEES FY REVENUE $45.3 MILLION TO $45.8 MILLION | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-11-14 12:30:00 | null | SEES FY 2019 REVENUE $43.6 MILLION TO $44.1 MILLION. | ZYNEX SEES FY 2019 REVENUE $43.6 MILLION TO $44.1 MILLION | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-10-29 18:30:00 | null | ZYNEX ANNOUNCES 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 REVENUE $11.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11 MILLION.Q3 EARNINGS PER SHARE $0.06.SEES Q4 REVENUE $12.3 MILLION TO $12.8 MILLION.SEES Q4 REVENUE UP ABOUT 32 TO 37 PERCENT.Q3 EARNINGS PER SHARE ESTIMATE $0.06 -- REFINITIV IBES DATA. | ZYNEX REPORTS Q3 EARNINGS PER SHARE OF $0.06 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-10-28 22:30:00 | null | ZYNEX, INC. HAS FILED A FOLLOW-ON EQUITY OFFERING IN THE AMOUNT OF $50 MILLION.
SECURITY NAME: COMMON STOCK
SECURITY TYPE: COMMON STOCK
TRANSACTION FEATURES: AT THE MARKET OFFERING | ZYNEX, INC. HAS FILED A FOLLOW-ON EQUITY OFFERING IN THE AMOUNT OF $50 MILLION. | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2019-10-16 22:30:00 | null | ZYNEX, INC., Q3 2019 EARNINGS CALL, OCT 29, 2019 | ZYNEX, INC., Q3 2019 EARNINGS CALL, OCT 29, 2019 | ZYXI | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object | 2020-08-06 20:30:00 | null | QTRLY BASIC LOSS PER SHARE $0.01.QTRLY ADJUSTED EARNINGS PER SHARE $0.14.REVENUES DECREASED BY $51.7 MILLION FROM $166.6 MILLION IN Q2 2019 TO $114.9 MILLION IN Q2 2020.Q2 EARNINGS PER SHARE VIEW C$-0.10, REVENUE VIEW C$77.2 MILLION -- REFINITIV IBES DATA. | SLEEP COUNTRY CANADA HOLDINGS INC REPORTS QTRLY ADJUSTED EARNINGS PER SHARE $0.14 | ZZZ.TO | a5c0a04e-eb88-4264-9cb2-fb3140e63537 | PressRelease |